But there’s a powerful fundamental story happening with Boston Scientific. Also, EPS is estimated to ramp higher this year by +13.8%. Now it makes sense why the stock has been powering to new ...

The following is a summary of “Arrhythmogenic Right Ventricular Cardiomyopathy: the importance of biventricular strain in risk-stratification,” published in the January 2025 issue of Cardiology by ...

Boston Scientific’s BSX robust expansion of operations across different geographies outside the United States is poised to help it grow in the upcoming quarters. The company’s ...